EBS · Emergent BioSolutions Inc.

Emergent BioSolutions reported a challenging first quarter of 2026, with total revenues declining 30% year-over-year to $156.1 million, primarily due to significant reductions in Medical Countermeasure (MCM) product sales. Smallpox MCM revenues fell 40% to $64.2 million, driven by lower ACAM2000 and TEMBEXA sales volumes, while Anthrax MCM revenues dropped 55% to $21.6 million due to lower international ANTHRASIL sales and reduced CYFENDUS deliveries to the U.S. government. These declines were partially offset by a notable increase in "Other Products" revenues, which rose 596% to $16.0 million on higher BAT sales. Commercial Products revenue decreased 5% to $42.9 million, attributed to an unfavorable price-volume mix for OTC NARCAN, despite market share maintenance.

Profitability metrics reflected the revenue pressures. GAAP net income fell 90% to $6.8 million, with margins compressing from 31% to 4%. Adjusted EBITDA decreased 55% to $35.6 million, though the margin remained resilient at 23%. Management highlighted that revenues exceeded the high end of their guidance range. Operating expenses decreased 15% to $145.6 million, driven by cost-saving initiatives and lower project spend, demonstrating operational discipline.

Strategically, the company is strengthening its financial position. It refinanced its term loan with a new $150 million facility maturing in 2031, aiming to reduce interest expenses and increase flexibility. The company secured over $200 million in new contract awards, including a significant multi-product agreement with the Government of Canada. Additionally, a new strategic manufacturing partnership with Substipharm Biologics for a Japanese Encephalitis vaccine and a $50 million share repurchase authorization signal management's focus on long-term growth and shareholder returns.